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Abstract: The aim of this study was to evaluate the effect of the melatonergic M1 and M2 receptor agonist and serotonergic 5-HT2C
receptor antagonist agomelatine on the spike wave discharges (SWDs) seen in electrocorticographic (ECoG) recordings of WAG/
Rij rats with absence epilepsy. Twenty-one WAG/Rij male rats were used in this study. Tripolar electrodes were placed on skulls and
control ECoG activities were recorded. Experimental groups received normal saline (Group I: 1 mL, intraperitoneally (i.p)), agomelatine
(Group II: 40 mg/kg, i.p), and melatonin (Group III: 40 mg/kg, i.p) injections for 7 days. Following this period, 2-h ECoG recordings
were repeated. The number of SWDs and their durations were calculated. The total number and duration of SWDs decreased in both the
agomelatine and melatonin groups. The systemic administration of agomelatine and melatonin attenuated the genetic absence epilepsy
seizures in WAG/Rij rats. The repressive effect of agomelatine on the absence seizures was similar to that of the melatonin used in this
study.
Key words: Absence epilepsy, agomelatine, melatonin, seizure, WAG/Rij rat

1. Introduction
Epilepsy, like many other chronic conditions, has complex
interactions with social and psychological functioning
(Aydın et al., 2013; Agar, 2015). Idiopathic generalized
epilepsy, including absence epilepsy (nonconvulsive), has
a genetic basis (Sarkisova and van Luijtelaar, 2011). WAG/
Rij rats were originally developed as a well-characterized
and validated genetic animal model of absence epilepsy
(Coenen and van Luijtelaar, 1987).
Pharmacological,
biochemical,
and
neuroendocrinological studies indicate a relationship between
different forms of epilepsy, including absence epilepsy,
and depression (Trinka et al., 2006; Mula and Schmitz,
2009; Sarkisova et al., 2010; Sarkisova and van Luijtelaar,
2011). Depressive disorders are the most common type
of psychiatric comorbidity in patients with epilepsy with
a lifetime prevalence of about 30% (Noe et al., 2011).
Treatment of depression usually requires long-term
drug treatment; therefore, the choice of antidepressant
medication must be made more carefully taking into
account the possible adverse effects on seizure threshold.
The scientific literature shows that most of the classical
* Correspondence: eragar@omu.edu.tr
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antidepressant drugs cause seizures in high doses in
humans and animals (Dailey and Naritoku, 1996). Sleep
disturbance is also prevalent among patients comorbid for
epilepsy and depressive disorder, and can independently
affect their quality of life (Bazil, 2003).
Several authors have reported altered circadian
rhythms in depressive disorders and there are consistent
findings about reduced daily secretion of melatonin
playing an important role in this process (Robillard
et al., 2013; Barylnik et al., 2014). Most of the studies
conducted to date indicate the presence of disturbances
in melatonin cycles in depressed patients (Beck-Friis,
1985; Rubin et al., 1992). Although a proconvulsant
effect of melatonin has been reported in a few studies
(Sandyk et al., 1992; Musshoff and Speckmann, 2003;
Stewart and Leung, 2005), the majority of experimental
and clinical studies show that melatonin has a protective
effect against epilepsy in humans (Banach et al, 2011)
and in experimental models of epilepsy (Champney et al.,
1996; Borowicz et al., 1999; Moezi et al., 2011; Yildirim
et al., 2013). Intraperitoneal administration of melatonin
increased the pentylenetetrazol (PTZ)-induced seizure
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and electroconvulsive threshold in mice (Borowicz et
al., 1999; Moezi et al., 2011). Chronic treatment with
melatonin reduced the incidence and mortality of PTZinduced seizures, whereas acute treatment with melatonin
did not affect them in male gerbils (Champney et al.,
1996). Moreover, intracerebroventricular injection of
melatonin reduced the mean frequency of penicillininduced epileptiform activity in rats (Yildirim et al., 2006).
Agomelatine is a novel antidepressant agent, which is
structurally homologous to melatonin. It is a potent MT1
and MT2 melatonin receptor agonist as well as a 5-HT2C
serotonin receptor antagonist. It was recently approved
as an antidepressant medication with comparable
efficacy to classical antidepressant drugs (Demyttenaere,
2011). In addition, agomelatine has been shown to
resynchronize altered circadian rhythms both in animals
(Fucs et al., 2006) and in humans (Leproult et al., 2005).
Agomelatine presented anticonvulsant effects on a variety
of experimental epilepsy models (Aguiar, 2012; Dastgheib
and Moezi, 2014). However, the anticonvulsant effects
of agomelatine and the melatonergic system were only
studied on convulsive epilepsy models. There is a complete
lack of information about effects of agomelatine on WAG/
Rij rats, which show spontaneous absence-like seizures.
Therefore, the effects of melatonin and agomelatine were
investigated on WAG/Rij rats with absence epilepsy in the
present study.
2. Materials and method
2.1. Animals
Twenty-one male adult WAG/Rij rats (6 months old)
with spontaneous absence epilepsy, weighing 250–300 g,
were used in this study. All described procedures were
approved by the local ethics committee of Gaziosmanpaşa
University (2012/009). Animals were housed in groups of
3 or 4 under environmentally controlled conditions (12-h
light/dark cycles at room temperature) and permitted free
access to food and water.
2.2. Experimental design
Animals were divided into the following experimental
groups:
Group I (control group): Normal saline (NS, 0.9%
NaCl w/v) was administered intraperitoneally (i.p.) in a
volume of 1 mL for 7 days.
Group II (agomelatine group): Agomelatine at a dose
of 40 mg/kg i.p. was administered in a volume of 1 mL for
7 days.
Group III (melatonin group): Melatonin at a dose of
40 mg/kg i.p. was administered in a volume of 1 mL for
7 days.
Each experimental group was composed of seven rats.
2.3. Surgical procedure
All animals were equipped with tripolar electrodes (MS
333/2A) for electrocorticographic (ECoG) recordings.

Before the surgery, they were anesthetized and sedated
with ketamine (100 mg/kg, i.p) + xylazine (10 mg/kg,
i.p). Rectal temperature was maintained at 37.5 °C by a
thermostatically controlled heating blanket (Kozan et al.,
2006). Animals were placed in a stereotaxic frame; the
skin and subcutaneous tissue were lifted off the bone and
folded back. Small burr holes were made into the skull
with a drill without damaging the dura and permanent
bipolar stainless steel electrodes (0.12 mm diam., Plastic
One, Roanoke, VA, USA) were unilaterally implanted in
the skulls of animals above the somatosensory cortex and
the motor cortex, stereotaxically (Cakil et al., 2011; Arslan
et al., 2013, 2014). The stereotaxic coordinates using the
bregma as a landmark were 2 mm anterior and 3.5 mm
lateral for the frontal electrode, and 6 mm posterior and
4 mm lateral for the occipital electrode (Paxinos and
Watson, 1998). A reference electrode was implanted over
the cerebellum. Electrodes were fixed to the skull with
dental cement. For postsurgery analgesia, rats received a
single intramuscular injection of 0.1 mg/kg buprenorphine
hydrochloride. After the surgery, animals were housed
individually.
2.4. Electrocorticographic recordings and analysis
After 5 days of healing, rats were placed individually in a
registration cage (25 × 30 cm in width, 35 cm high) and
connected to recording leads. One day before the ECoG
recording session, rats were moved to Plexiglas recording
cages and allowed to habituate to the recording procedure
for 2 h. All ECoG recordings were obtained between 0900
and 1200 hours using AcqKnowledge software (version
3.8) and the MP-150 multichannel physiological analysis
system (BIOPAC Systems Inc., Goleta, CA, USA) from
free-moving animals in a noise-isolated room. Rats were
continuously observed throughout the recording. After
the drug administration procedure, rats were connected to
recording leads again and after treatment. Seizures were
assessed with offline analysis of spike wave discharges
(SWDs) on the recordings. Total number and cumulative
length of SWDs in the recordings were used for evaluating
the seizures.
2.5. Drugs and drug administration
Sterile physiological normal saline, ethanol, ketamine
hydrochloride (HCl) and xylazine hydrochloride,
melatonin, and agomelatine (Sigma Chemical Co., St.
Louis, MO, USA) were used. Melatonin and agomelatine
were dissolved in 1% ethyl alcohol. The required doses
were administered i.p. in a volume of 1 mL for 7 days.
The moderate doses of the drugs were determined in
accordance with previous studies (Yildirim and Marangoz,
2006; Dastgheib and Moezi, 2014; Demir Özkay et al.,
2015).
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2.6. Statistical analysis
Statistical analyses of each parameter were performed
using SPSS 15.00. Comparison of ECoG recordings of the
same groups before and after drug administration were
made by paired-sample t-tests. The results are given as
mean ± standard error of mean (SEM). For all statistical
tests, P < 0.05 was considered statistically significant.
3. Results
SWD numbers and durations are shown in Figures 1A–
1D. In the control group, the total number of SWDs for
a 2-h epoch was 58.43 ± 4.24 with a mean total duration
of 348.7 ± 33.94 s (Figure 1A). After 1 week of NS
administration, the total number of SWDs was 58.86 ±

4.26 and their mean duration was 344.3 ± 40.75 s (Figure
1B). The administration of NS for 7 days did not alter the
total number of SWDs (Figure 2) or the mean duration of
SWDs (Figure 3) (P > 0.05).
The total number of SWDs was 59.86 ± 5.77 and 34.57
± 3.40 and their mean durations were 349.9 ± 44.29 and
154.5 ± 17.31 s before and after 1 week of agomelatine
injection, respectively (Figure 1C). The total number of
SWDs was 60.57 ± 5.84 and 36.29 ± 3.99 and their mean
durations were 345.0 ± 49.71 and 169.5 ± 32.08 s before and
after 1 week of melatonin injection, respectively (Figure
1D). Both melatonin (40 mg/kg, i.p.) and agomelatine
(40 mg/kg, i.p.) significantly decreased the total number
(P < 0.05) (Figure 2) and the mean duration (P < 0.05)

30 s

2s

Figure 1. (A) The total number and duration of SWDs for 2-h epoch were 58.4 ± 4.2 and 348.7 ± 33.9 s in WAG/Rij rats with genetic
absence epilepsy, respectively. (B) Administration of normal saline (1 mL, i.p) for 7 days did not alter the total number and duration
of SWDs in WAG/Rij rats with genetic absence epilepsy. (C) Administration of agomelatine (40 mg/kg, i.p) for 7 days significantly
decreased the total number and duration of SWDs to 34.5 ± 3.4 and 154.5 ± 17.3 s in WAG/Rij rats with genetic absence epilepsy, respectively. (D) Administration of melatonin (40 mg/kg, i.p) for 7 days significantly decreased the total number and duration of SWDs
to 36.2 ± 3.9 and 169.5 ± 32.0 s in WAG/Rij rats with genetic absence epilepsy, respectively.
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Figure 2. The effects of intraperitoneal administration of agomelatine and melatonin on the total number of SWDs in WAG/Rij rats with
genetic absence epilepsy. The administration of agomelatine and melatonin at a dose of 40 mg/kg for 7 days significantly decreased the
total number of SWDs (P < 0.05). Normal saline did not alter the total number of SWDs in WAG/Rij rats (P > 0.05).
**: P < 0.05, significant differences compared to their own basal records.

(Figure 3) of SWDs in the ECoG recordings. There were
no significant differences regarding the SWD parameters
between the melatonin and agomelatine groups (P > 0.05).

The total duration of SWDs (s)

4. Discussion
The results of the present study revealed that subchronic
and systemic administration of agomelatine doses showed
a considerable antiepileptic effect similar to melatonin on
absence seizures in WAG/Rij rats.

Most of the evidence has suggested that melatonin
has a prominent role in epilepsy. Significant changes were
found in day–night melatonin levels during convulsions
in patients with intractable epilepsy (Bazil et al., 2000).
The level of melatonin dramatically increased following
seizures (Bazil et al., 2000). Melatonin has also been shown
to exert an anticonvulsant activity in various animal
models of seizures (Costa-Lotufo et al., 2002; Yalyn et al.,
2006; Yildirim and Marangoz, 2006) and reduced spiking

Figure 3. The effects of intraperitoneal administration of agomelatine and melatonin on the total duration of SWDs in WAG/Rij rats
with genetic absence epilepsy. The administration of agomelatine and melatonin at a dose of 40 mg/kg for 7 days significantly decreased
the total duration of SWDs (P < 0.05). Normal saline did not alter the total number of SWDs in WAG/Rij rats (P > 0.05).
**: P < 0.05, significant differences compared to their own basal records.
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activity and seizure frequency in patients with intractable
epilepsy (Antón-Tay, 1974). Furthermore, Tchekalarova
(2013) demonstrated that melatonin attenuated seizure
frequency and protected against various behavioral
alterations, memory deficits, and neuronal damage
during the chronic epileptic state in a kainate model of
temporal lobe epilepsy. Melatonin, at doses of 40 and 80
mg/kg, showed an anticonvulsant effect on PTZ-induced
clonic seizure threshold in mice, whereas the melatonin
dose of 20 mg/kg did not alter the threshold of clonic
seizure (Moezi et al., 2011). In line with previous studies,
the moderate dose of melatonin (40 mg/kg) reduced the
total number and duration of SWDs in WAG/Rij rats
with absence epilepsy in the present study. In contrast,
chronic administration of melatonin, at a dose of 10 mg/
kg, for 14 days did not affect the frequency of penicillininduced epileptiform activity in rats (Yildirim et al., 2013).
However, pinealectomy reduced latency to the onset of
initial epileptiform discharges and significantly increased
the frequency of penicillin-induced epileptiform activity
in rats (Yildirim et al., 2013). Moreover, Stewart and Leung
(2005) suggested that nocturnal activation of hippocampal
Mel(1b) receptors depresses GABA(A) receptor function
in the hippocampus, resulting in enhanced seizure
susceptibility in male rats.
The molecular mechanisms underlying antiepileptic
activity of melatonin were suggested as enhancement of
norepinephrine secretion through adrenergic receptors
(Reiter et al., 2007), reduction of striatal dopaminergic
activity through dopaminergic D1 and D2 receptors
(Sweis, 2005), downregulation of glutamate secretion
through blockage of nitric oxide generation (Munoz
Hoyos et al., 1998), and upregulation of GABA release
in hippocampus (Stewart and Leung, 2005). However,
none of these studies explained the antiepileptic activity
of melatonin in absence epilepsy, since absence epilepsy is
related to a predominance of inhibitory activity in contrast
to convulsive seizures, where an excess of excitatory activity
is present (Tolmacheva and van Luijtelaar, 2007; Ngomba
et al., 2011; D’Amore et al., 2013; Kovacs et al., 2015).
Generation of absence seizures is thought to be associated
with excessive thalamic oscillations, due to abnormal
intrinsic neuronal properties under the control of an
inhibitory GABAergic mechanism (Steriade et al., 1993;
Manning et al., 2003; Kovacs et al., 2015). On the other
hand, melatonin shows anticonvulsant activity due to its
antioxidant, antiexcitotoxic, and free radical-scavenging
properties in various experimental epilepsy models and
human studies (Floreani et al., 1999; Srivastava et al.,
2002; Gupta et al., 2004; Lima et al., 2011; Nazıroğlu et
al., 2013; Yürüker et al., 2015). However, absence seizures
do not cause serious excitotoxic damages as seen in
convulsive seizures, because of less free radical generation.
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Interestingly, melatonin was also able to reduce the total
number and duration of SWDs of absence epilepsy in
this study. Further studies are needed to assess possible
molecular mechanisms for these findings.
Subchronic administration of agomelatine between
doses of 20 and 75 mg/kg showed antiepileptic effects
in different experimental epilepsy models (Aguiar et
al., 2012; Dastgheib et al., 2014). Agomelatine showed a
significant increase in latency to convulsion (at doses of
25 or 50 mg/kg) and also significantly increased the time
until death (at doses of 50 or 75 mg/kg) in PTZ-induced
and pilocarpine-induced epilepsy, whereas agomelatine
caused no significant alterations in latency to convulsions
or time until death in the strychnine-, electroshock-,
and picrotoxin-induced seizure models (Aguiar et al.,
2012). Moreover, a single dose of agomelatine (50 or 75
mg/kg) had an anticonvulsant effect on PTZ-induced
seizures (Dastgheib and Moezi, 2014). Moderate doses of
agomelatine were used (40 mg/kg) in the present study.
Agomelatine attenuated both the total number and total
duration of SWDs in absence epilepsy of WAG/Rij rats.
Although agomelatine is not only a potent melatonin
receptor agonist but also acts as a 5-HT2C antagonist,
the affinity of agomelatine for the 5-HT2C receptor is
in the micromolar range and about 100-fold less than
its affinity for melatonin receptors. The results of the
present study provide evidence that 5-HT2C antagonism
did not provide a synergistic antiepileptic action to the
melatonergic system in an absence model of epilepsy, since
there was no significant difference between the effects of
melatonin and agomelatine used in this study, suggesting
the anticonvulsant effect of both substances in the absence
model of epilepsy.
Agomelatine is the first antidepressant that was
developed based on a hypothesis relating circadian
rhythms and depression (Bodinat et al., 2010). Absence
seizures are also reported to be closely related to mood and
especially to sleep time and quality. Though they can only
be identified in awake patients, seizure discharges were
shown to occur more frequently in sleep (Drinkenburg
et al., 2001). Neurotransmitter levels that mediate
the epileptic activity are also known to be influenced
by circadian cycles (Yehuda and Mostofsky, 1993). A
circadian effect of melatonin is attributed to the MT1 and
MT2 subtypes of human melatonin receptors, on which
agomelatine has agonist effects. Agomelatine also shows
a longer half-life and greater affinity for MT1 and MT2
melatonin receptors in different brain areas (Delagrange
and Boutin, 2006). Considering the data mentioned
above, agomelatine may have a therapeutic effect on
sleep disorders induced by absence seizures and may also
alleviate epileptic discharges indirectly by improving sleep
quality and circadian rhythm.
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In conclusion, these data for the first time illustrate that
the systemic administration of agomelatine and melatonin
attenuated the number and duration of SWDs seen in the
ECoG recordings of genetic absence epilepsy seizures in
WAG/Rij rats. The repressive effect of agomelatine on

the absence seizures was found to be similar to that of
melatonin. Agomelatine seems to be recommendable
as a potential drug for absence epilepsy and many other
complications such as depression and sleep disorders
associated with epilepsy.

References
Agar E (2015). The role of cannabinoids and leptin in neurological
diseases. Acta Neurol Scand (in press).
Aguiar CC, Almeida AB, Araujo PV, Vasconcelos GS, Chaves EM, do
Vale OC, Macedo DS, de Sousa FC, Viana GS, Vasconcelos SM
(2012). Anticonvulsant effects of agomelatine in mice. Epilepsy
Behav 24: 324–328.
Antón-Tay F (1974). Melatonin: effects on brain function. Adv
Biochem Psychopharmacol 11: 315–324.
Arslan G, Alici SK, Ayyildiz M, Agar E (2013). The role of CB1receptors in the proconvulsant effect of leptin on penicillininduced epileptiform activity in rats. CNS Neurosci Ther 19:
222–228.
Arslan G, Ayyildiz M, Agar E (2014). The interaction between ghrelin
and cannabinoid systems in penicillin-induced epileptiform
activity in rats. Neuropeptides 48: 345–352.

Champney TH, Hanneman WH, Legare ME, Appel K (1996). Acute
and chronic effects of melatonin as an anticonvulsant in male
gerbils. J Pineal Res 20: 79–83.
Coenen AM, van Luijtelaar EL (1987). The WAG/Rij rat model for
absence epilepsy: age and sex factors. Epilepsy Res 1: 297–301.
Costa-Lotufo LV, Fonteles MMF, Lima ISP, de Oliveira AA,
Nascimento VS, de Bruin VM, Viana GS (2002). Attenuating
effects of melatonin on pilocarpine-induced seizures in rats.
Comp Biochem Physiol C Toxicol Pharmacol 131: 521–529.
Dailey JW, Naritoku DK (1996). Antidepressants and seizures: clinical
anecdotes overshadow neuroscience. Biochem Pharmacol 52:
1323–1329.
D’Amore V, Santolini I, van Rijn CM, Biagioni F, Molinaro G, Prete
A, Conn PJ, Lindsley CW, Zhou Y, Vinson PN et al. (2013).
Potentiation of mGlu5 receptors with the novel enhancer,
VU0360172, reduces spontaneous absence seizures inWAG/
Rij rats. Neuropharmacology 66: 330–338.

Aydın D, Yıldırım M, Ayyıldız M, Ağar E (2013). The effect of
combined treatment of alpha-tocopherol, ascorbic acid and
pyridoxine with NMDA blocker, memantine on penicillin
induced epileptiform activity in rats. Turk J Med Sci 43: 245–
250.

Dastgheib M, Moezi L (2014). Acute and chronic effects
of agomelatine on intravenous penthylenetetrazol-induced
seizure in mice and the probable role of nitric oxide. Eur J
Pharmacol 736: 10–15.

Banach M, Gurdziel E, Jedrych M, Borowicz KK (2011). Melatonin
in experimental seizures and epilepsy. Pharmacol Rep 63: 1–11.

Delagrange P, Boutin JA (2006). Therapeutic potential of melatonin
ligands. Chronobiol Int 23: 413–418.

Barylnik JB, Filippova NV, Trayber LV( 2014). Modern approaches
to the synchronization of circadian rhythms in treatment of
depression. Zh Nevrol Psikhiatr Im S S Korsakova 114: 124–
128.

Demir Özkay Ü, Söztutar E, Can ÖD, Üçel Uİ, Öztürk Y, Ulupinar
E (2015). Effects of long-term agomelatine treatment on the
cognitive performance and hippocampal plasticity of adult
rats. Behav Pharmacol 26: 469–480.

Bazil CW (2003). Epilepsy and sleep disturbance. Epilepsy Behav 4:
39–45.
Bazil CW, Short D, Crispin D, Zheng W (2000). Patients with
intractable epilepsy have low melatonin, which increases
following seizures. Neurology 55: 1746–1748.
Beck-Friis J (1985). Serum melatonin in relation to clinical variables
in patients with major depressive disorder and a hypothesis of
a low melatonin syndrome. Acta Psychiatr Scand 71: 319–330.
Bodinat CD, Lemaitre GB, Mocaer E, Renard P, Muñoz C, Millan
MJ (2010). Agomelatine, the first melatonergic antidepressant:
discovery, characterization and development. Nat Rev Drug
Discov 9: 628–642.
Borowicz KK, Kaminski R, Gasior M, Kleinrok Z, Czuczwar SJ
(1999). Influence of melatonin upon the protective action of
conventional anti-epileptic drugs against maximal electroshock
in mice. Eur Neuropsychopharmacol 9: 185–190.
Cakil D, Yildirim M, Ayyildiz M, Agar E (2011). The effect of coadministration of the NMDA blocker with agonist and
antagonist of CB1-receptor on penicillin-induced epileptiform
activity in rats. Epilepsy Res 93: 128–133.

Demyttenaere K (2011). Agomelatine: a narrative review. Eur
Neuropsychopharmacol 4: S703–S709.
Drinkenburg WH, Coenen AM, Vossen JM, van Luijtelaar E L
(2001). Spike-wave discharges and sleep-wake states in rats
with absence epilepsy. Epilepsy Res 2: 218–224.
Floreani M, Skaper SD, Facci L, Lipartiti M, Giusti P (1997).
Melatonin maintains glutathione homeostasis in kainic acidexposed rat brain tissues. FASEB J 11: 1309–1315.
Fuchs E, Simon M, Schmelting B (2006). Pharmacology of a new
antidepressant: benefit of the implication of the melatonergic
system. Int Clin Psychopharmacol 1: S17–S20.
Gupta M, Gupta YK, Agarwal S, Aneja S, Kalaivani M, Kohli
K (2004). Effects of add-on melatonin administration
on antioxidant enzymes in children with epilepsy taking
carbamazepine monotherapy: a randomized, double-blind,
placebo-controlled trial. Epilepsia 45: 1636–1639.
Kovacs Z, Kekesi KA, Dobolyi A, Lakatos R, Juhasz G (2015).
Absence epileptic activity changing effects of non-adenosine
nucleoside inosine, guanosine and uridine in Wistar Albino
Glaxo Rijswijk rats. Neuroscience 6: 593–608.

909

AYGÜN et al. / Turk J Biol
Kozan R, Ayyildiz M, Yildirim M, Agar E (2006). The effects
of ethanol intake and withdrawal on penicillin-induced
epileptiform activity in rats. Brain Res Bull 71: 111–115.
Leproult R, Van Onderbergen A, L’hermite-Baleriaux
M, Van Cauter E, Copinschi G (2005). Phaseshifts of 24-h rhythms of hormonal release and body
temperature following early evening administration of
the melatonin agonist agomelatine in healthy older men. Clin
Endocrinol 63: 298–304.
Lima E, Cabral FR, Cavalheiro EA, Naffah-Mazzacoratti MG, Amado
D (2011). Melatonin administration after pilocarpine-induced
status epilepticus: a new way to prevent or attenuate postlesion
epilepsy? Epilepsy Behav 20: 607–612.
Manning JP, Richards DA, Bowery NG (2003). Pharmacology of
absence epilepsy. Trends Pharmacol Sci 24: 542–549.
Moezi L, Shafaroodi H, Hojati A, Dehpour AR (2011). The interaction
of melatonin and agmatine on pentylenetetrazole-induced
seizure threshold in mice. Epilepsy Behav 22: 200–206.
Mula M, Schmitz B (2009). Depression in epilepsy: mechanisms and
therapeutic approach. Ther Adv Neurol Dis 2: 337–344.
Munoz Hoyos A, Molina Carballo A, Macias M, Rodriguez Cabezas
T, Martin Medina E, Narbona Lopez E, Valenzuela Ruiz A,
Acuna Castroviejo D (1998). Comparison between tryptophan
methoxyindole and kynurenine metabolic pathways in normal
and preterm neonates and in neonates with acute fetal distress.
Eur J Endocrinol 139: 89–95.
Musshoff U, Speckmann EJ (2003). Diurnal actions of melatonin
on epileptic activity in hippocampal slices of rats. Life Sci 73:
2603–2610.
Nazıroğlu M, Yüksel M, Köse SA, Özkaya MO (2013). Recent reports
of Wi-Fi and mobile phone-induced radiation on oxidative
stress and reproductive signaling pathways in females and
males. J Membr Biol 246: 869–875.
Ngomba RT, Santolini I, Biagioni F, Molinaro G, Simonyi
A, van Rijn CM, D’Amore V, Mastroiacovo F, Olivieri
G, Gradini R et al. (2011). Protective role for type-1
metabotropic glutamate receptors against spike and wave
discharges in the WAG/Rij rat model of absence epilepsy.
Neuropharmacology 60: 1281–1291.
Noe KH, Locke DEC, Sirven JI (2011). Treatment of depression in
patients with epilepsy. Curr Treat Option N 13: 371–379.
Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic
Coordinates. 4th ed. New York, NY, USA: Academic Press.
Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ,
Koppisepi S (2007). Medical implications of melatonin:
receptor-mediated and receptor-independent actions. Adv
Med Sci 52: 11–28.
Robillard R, Naismith SL, Rogers NL, Scott EM, Ip
TK, Hermens DF, Hickie IB (2013). Sleep-wake cycle
and melatonin rhythms in adolescents and young adults
with mood disorders: comparison of unipolar and bipolar
phenotypes. Eur Psychiatry 28: 412–416.
Rubin RT, Heist EK, McGeoy SS, Hanada K, Lesser IM (1992).
Neuroendocrine aspects of primary endogenous depression.
XI. Serum melatonin measures in patients and matched control
subjects. Arch Gen Psychiatry 49: 558–567.

910

Sandyk R, Tsagas N, Anninos PA (1992). Melatonin as a proconvulsive
hormone in humans. Int J Neurosci 63: 125–135.
Sarkisova KY, Kuznetsova GD, Kulikov MA, van Luijtelaar G (2010).
Spike-wave discharges are necessary for the expression of
behavioral depression-like symptoms. Epilepsia 51: 146–160.
Sarkisova K, van Luijtelaar G (2011). The WAG/Rij strain: a genetic
animal model of absence epilepsy with comorbidity of
depression. Prog Neuropsychopharmacol Biol Psychiatry 35:
854–876.
Srivastava AK, Gupta SK, Jain S, Gupta YK (2002). Effect of
melatonin and phenytoin on an intracortical ferric chloride
model of posttraumatic seizures in rats. Methods Find Exp
Clin Pharmacol 24: 145–149.
Steriade M, McCormick DA, Sejnowski J (1993). Thalamocortical
oscillations in the sleeping and aroused brain. Science 262:
679–685.
Stewart LS, Leung LS (2005). Hippocampal melatonin receptors
modulate seizure threshold. Epilepsia 46: 473–480.
Sweis D (2005). The uses of melatonin. Arch Dis Child Educ Pract
Ed 90: 74–77.
Tchekalarova J, Petkova Z, Pechlivanova D, Moyanova S, Kortenska
L, Mitreva R, Lozanov V, Atanasova D, Lazarov N, Stoynev
A (2013). Prophylactic treatment with melatonin after status
epilepticus: effects on epileptogenesis, neuronal damage and
behavioral changes in kainate model of temporal lobe epilepsy.
Epilepsy Behav 27: 174–187.
Tolmacheva EA, van Luijtelaar G (2007). Absence seizures are
reduced by the enhancement of GABA-ergic inhibition in the
hippocampus in WAG/Rij rats. Neurosci Lett 416: 17–21.
Trinka E, Kienpointner G, Unterberger I, Luef G, Bauer G, Doering
LB, Doering S (2006). Psychiatric comorbidity in juvenile
myoclonic epilepsy. Epilepsia 47: 2086–2091.
Yalyn O, Arman F, Erdogan F, Kula M (2006). A comparison of
the circadian rhythms and the levels of melatonin in patients
with diurnal and nocturnal complex partial seizures. Epilepsy
Behav 8: 542–546.
Yehuda S, Mostofsky DI (1993). Circadian effects of beta-endorphin,
melatonin, DSIP, and amphetamine on pentylenetetrazoleinduced seizures. Peptides 14: 203–205.
Yildirim M, Aydin-Abidin S, Abidin I, Akca M, Canpolat S, Cansu
A (2013). Evaluation of the role of chronic daily melatonin
administration and pinealectomy on penicillin-induced focal
epileptiform activity and spectral analysis of ECoG in rats: an
in vivo electrophysiological study. Neurochem Res 38: 1672–
1685.
Yildirim M, Marangoz C (2006). Anticonvulsant effects of melatonin
on penicillin-induced epileptiform activity in rats. Brain Res
1099: 183–188.
Yürüker V, Nazıroğlu M, Şenol N (2015). Reduction in traumatic
brain injury-induced oxidative stress, apoptosis, and calcium
entry in rat hippocampus by melatonin: possible involvement
of TRPM2 channels. Metab Brain Dis 30: 223–231.

